Media

Corgentech to Announce Fourth Quarter and Year-End 2004 Financial Results and Host Webcast Conference Call on February 3, 2005

SOUTH SAN FRANCISCO, Calif., Feb 01, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, will announce financial results for the fourth quarter and year-end 2004 after the markets close on Thursday, February 3, 2005 and will hold a webcast teleconference at 4:30 p.m. EST that day. John McLaughlin, Corgentech's president and chief executive officer, and Richard Powers, vice president and chief financial officer, intend to discuss financial results from the fourth quarter and full year 2004 as well as additional information from PREVENT III, the company's Phase 3 trial of E2F Decoy for the treatment of peripheral bypass graft failures.

Interested parties can listen to the live audio webcast, or the subsequent archived recording, by logging on to www.corgentech.com and going to the Investor Information page. Please connect to Corgentech's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by calling 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 3654405. The webcast will be available until the company's next quarterly financial results conference call.

About Corgentech

Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, and cancer. For more information on the company and its technologies, visit www.corgentech.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Act of 1995. These include without limitation statements related to our clinical trials, product candidates, and operations. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of our clinical trials, intellectual property matters, difficulties or delays in obtaining regulatory approval, manufacturing our lead product candidate, competition from other pharmaceutical or biotechnology companies, our ability to obtain additional financing to support our operations and other risks detailed in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2003 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2004. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corgentech undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date hereof.

SOURCE Corgentech Inc.

Jennifer Cook Williams, Senior Director, Investor Relations of Corgentech Inc.,
+1-650-624-9600, or [email protected]

http://www.prnewswire.com

News Provided by COMTEX